Citadel Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $305K | Sell |
12,300
-37,400
| -75% | -$891K | ﹤0.01% | 10435 |
|
|
2025
Q4 | $1.16M | Buy |
49,700
+31,800
| +178% | +$708K | ﹤0.01% | 7063 |
|
|
2025
Q3 | $353K | Buy |
+17,900
| New | +$368K | ﹤0.01% | 9980 |
|
|
2025
Q2 | – | Sell |
-21,200
| Closed | -$514K | – | 12861 |
|
|
2025
Q1 | $514K | Buy |
21,200
+7,800
| +58% | +$176K | ﹤0.01% | 8410 |
|
|
2024
Q4 | $280K | Buy |
13,400
+5,700
| +74% | +$122K | ﹤0.01% | 9797 |
|
|
2024
Q3 | $153K | Sell |
7,700
-700
| -8% | -$13K | ﹤0.01% | 10540 |
|
|
2024
Q2 | $130K | Sell |
8,400
-3,000
| -26% | -$46.7K | ﹤0.01% | 10545 |
|
|
2024
Q1 | $182K | Sell |
11,400
-24,500
| -68% | -$369K | ﹤0.01% | 10471 |
|
|
2023
Q4 | $603K | Buy |
35,900
+22,000
| +158% | +$301K | ﹤0.01% | 7686 |
|
|
2023
Q3 | $162K | Sell |
13,900
-34,500
| -71% | -$461K | ﹤0.01% | 10229 |
|
|
2023
Q2 | $650K | Sell |
48,400
-17,000
| -26% | -$245K | ﹤0.01% | 7359 |
|
|
2023
Q1 | $1.08M | Buy |
65,400
+40,000
| +157% | +$660K | ﹤0.01% | 6594 |
|
|
2022
Q4 | $472K | Sell |
25,400
-15,800
| -38% | -$243K | ﹤0.01% | 8364 |
|
|
2022
Q3 | $529K | Buy |
41,200
+23,900
| +138% | +$283K | ﹤0.01% | 8336 |
|
|
2022
Q2 | $121K | Buy |
+17,300
| New | +$127K | ﹤0.01% | 11205 |
|
|
2022
Q1 | – | Sell |
-22,200
| Closed | -$150K | – | 13711 |
|
|
2021
Q4 | $150K | Buy |
22,200
+11,700
| +111% | +$76.9K | ﹤0.01% | 12254 |
|
|
2021
Q3 | $56K | Buy |
+10,500
| New | +$57.4K | ﹤0.01% | 13306 |
|
|
2021
Q2 | – | Sell |
-39,900
| Closed | -$184K | – | 13739 |
|
|
2021
Q1 | $184K | Buy |
39,900
+19,500
| +96% | +$77.5K | ﹤0.01% | 11799 |
|
|
2020
Q4 | $68K | Sell |
20,400
-2,000
| -9% | -$6.72K | ﹤0.01% | 10436 |
|
|
2020
Q3 | $67K | Buy |
22,400
+2,700
| +14% | +$10.6K | ﹤0.01% | 9480 |
|
|
2020
Q2 | $91K | Sell |
19,700
-6,300
| -24% | -$28.3K | ﹤0.01% | 9041 |
|
|
2020
Q1 | $100K | Buy |
+26,000
| New | +$107K | ﹤0.01% | 8634 |
|
|
2019
Q4 | – | Sell |
-18,000
| Closed | -$96K | – | 9184 |
|
|
2019
Q3 | $96K | Buy |
+18,000
| New | +$95.9K | ﹤0.01% | 8500 |
|
|
2019
Q2 | – | Sell |
-10,900
| Closed | -$56K | – | 9243 |
|
|
2019
Q1 | $56K | Buy |
+10,900
| New | +$32K | ﹤0.01% | 8778 |
|
|
2018
Q4 | – | Sell |
-18,200
| Closed | -$69K | – | 9179 |
|
|
2018
Q3 | $69K | Buy |
+18,200
| New | +$57K | ﹤0.01% | 8716 |
|
|
2017
Q4 | – | Sell |
-10,500
| Closed | -$26K | – | 8006 |
|
|
2017
Q3 | $26K | Sell |
10,500
-2,000
| -16% | -$5.49K | ﹤0.01% | 7315 |
|
|
2017
Q2 | $35K | Buy |
+12,500
| New | +$26.1K | ﹤0.01% | 7173 |
|
|
2016
Q1 | – | Sell |
-1,300
| Closed | -$3K | – | 6929 |
|
|
2015
Q4 | $3K | Sell |
1,300
-2,300
| -64% | -$6.59K | ﹤0.01% | 8524 |
|
|
2015
Q3 | $11K | Buy |
3,600
+2,400
| +200% | +$10.4K | ﹤0.01% | 8429 |
|
|
2015
Q2 | $5K | Sell |
1,200
-700
| -37% | -$2.79K | ﹤0.01% | 8537 |
|
|
2015
Q1 | $8K | Buy |
1,900
+800
| +73% | +$2.88K | ﹤0.01% | 8236 |
|
|
2014
Q4 | $3K | Sell |
1,100
-7,800
| -88% | -$21.4K | ﹤0.01% | 8331 |
|
|
2014
Q3 | $30K | Buy |
8,900
+5,700
| +178% | +$14.9K | ﹤0.01% | 7216 |
|
|
2014
Q2 | $8K | Buy |
3,200
+800
| +33% | +$1.71K | ﹤0.01% | 7625 |
|
|
2014
Q1 | $5K | Buy |
2,400
+1,400
| +140% | +$2.93K | ﹤0.01% | 7641 |
|
|
2013
Q4 | $2K | Buy |
+1,000
| New | +$2.02K | ﹤0.01% | 6901 |
|
Other funds holding CPRX
VCM
DM
VPM
Citadel Advisors's CPRX Position: Q1 2026 in Review
Citadel Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 88% in Q1 2026, buying an estimated $6.49M and bringing the position to 581,093 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.
Citadel Advisors first reported a position in CPRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $17.8M in Q1 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Citadel Advisors held 581,093 shares of Catalyst Pharmaceutical worth $14.4M as of Q1 2026.
- Citadel Advisors bought 272,622 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.49M.
- Catalyst Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2736 holding.
- Citadel Advisors first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's Catalyst Pharmaceutical position peaked at $17.8M in Q1 2024.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.